试验雷达 AI | ||
|---|---|---|
临床试验 NCT06787560 针对骨髓衰竭综合征目前招募中。请查看临床试验雷达卡片视图和 AI 发现工具了解所有详情，或在此提出任何问题。 | ||
浙江大学CD7 CAR-T Cell Sequential Allo-HSCT for Non-malignant Blood and Immune System Diseases 早期I期 20
Clinical Study on the Safety and Efficacy of CD7 CAR-T Cell Sequential Allogeneic Hematopoietic Stem Cell Transplantation for Non-malignant Blood and Immune System Diseases
- TXB2024023
Allo-HSCT
Immuno Deficiency Disorders
| 参与者组/试验组 | 干预措施/治疗方法 |
|---|---|
实验性CD7 CAR-T cells（ CD7 chimeric antigen receptor T cells） Patients or donors undergo leukapheresis. Patients will receive a lymphodepletion chemotherapy with CTX、Flu、VP-16 before CAR-T cells infusion. CAR-T cells could be transfused after 48 hours of preconditioning. | CD7 CAR-T cells injection Each subject receive CD7 CAR T-cells by intravenous infusion 异基因造血干细胞移植 (allo-HSCT) allogeneic hematopoietic stem cell transplantation |
| 结果指标 | 度量标准描述 | 时间框架 |
|---|---|---|
Incidence of treatment-emergent adverse events (TEAEs) | Incidence of treatment-emergent adverse events | Up to 2 years after Treatment |
Transplant related mortality rate | The proportion of patients who died after transplantation to the total number of transplant patients during the same period | Up to 100 days after Treatment |
| 结果指标 | 度量标准描述 | 时间框架 |
|---|---|---|
Allogeneic hematopoietic stem cell transplant implantation rate | The proportion of the number of patients who achieved hematopoietic reconstitution to the total number of allogeneic hematopoietic stem cell transplantation patients in the same period. | Up to 100 days after Treatment |
Time to neutrophil and platelet engraftment | The time for neutrophils and platelets to reach the implantation criteria after stem cell reinfusion | Up to 30 days after Treatment |
Disease-feesurvival，DFS | The proportion of disease-free patients who survived to the total number of patients who transplanted allogeneic hematopoietic stem cells during the same period. | Up to 2 years after Treatment |
Overall survival, OS | After transplantation until death from any cause. | Up to 2 years after Treatment |
1. Non-malignant blood and immune system diseases include: hereditary bone marrow failure, congenital immune deficiency, hemoglobinopathy and other non-malignant blood and immune system diseases,
- Confirmed hereditary bone marrow failure syndrome. Including: Fanconi anemia, congenital pure red cell aplastic anemia, congenital dyskeratosis, Scheux-Day syndrome, congenital neutropenia, various bone marrow failure related congenital thrombocytopenia and other unclassified congenital bone marrow exhaustion diseases;
- It meets the criteria of clinical manifestation, immune function and gene diagnosis of immune deficiency disease;
- Diagnosed with hemoglobinopathy and dependent on blood transfusions; serum ferritin levels are < 3000 μg/L, with cardiac and hepatic iron content indicating moderate or lower iron overload; documentation of iron chelation therapy (including prescriptions or invoices) for at least three months prior to screening is available; no hydroxyurea, ruxolitinib, decitabine, or cytarabine has been administered in the three months preceding enrollment. The spleen size must not extend beyond the umbilical horizontal line or the midline of the abdomen. Allogeneic hematopoietic stem cell transplantation (allo-HSCT) is indicated, and suitable donors for related allo-HSCT are available.
2. Serum total bilirubin ≤1.5 times the upper limit of normal value, serum Alanine aminotransferase (ALT) and Aspartate aminotransferase (AST) ≤ 3 times the upper limit of normal value range;
3. Echocardiography showed Left ventricular ejection fraction (LVEF) >50%;
4. Pulse oxygen saturation ≥92% (non-oxygen state);
5. The estimated survival is more than 3 months;
6. ECOG score 0-1;
7. Abdominal B-ultrasonography and other examinations were performed to evaluate spleen size. Splenectomy should be evaluated before transplantation for patients with giant spleen;
8. Women and men who are fertile must consent to the use of appropriate contraception before entering the study, during study participation, and for 6 months after transfusion (the safety of this therapy for the unborn child is not known, with unknown risks);
9. Subjects who are willing to participate in the study are able to understand and have the ability to sign informed consent.
- 1. People with a history of epilepsy or other central nervous system disorders;
- 2. Epstein-Barr virus (EBV) DNA positive;
- 3. People with a history of prolonged QT interval or serious heart disease;
- 4. People with active hepatitis B or C virus;
- 5. Tuberculosis, AIDS and other major infectious diseases;
- 6. Sepsis, pulmonary infection, intestinal infection and other major organ infection and poor control, and/or hypersensitive C-reactive protein, procalcitonin significantly elevated;
- 7. People who have previously received other clinical studies and gene therapy;
- 8. Any situation that the investigator believes may increase the risk to the subject or interfere with the test results.
Yake Biotechnology Ltd.Zhejiang